SCHEMBL16631767

SCHEMBL16631767

Cc1cn2cc(C)c(=O)[nH]c2nc1=O

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.34
RAB9A P51151 2/20 0.33
HPGD P15428 2/20 0.33
ATAD2 Q6PL18 1/20 0.32
BRD4 O60885 1/20 0.32
ADORA3 P0DMS8 1/20 0.30
TNKS O95271 1/20 0.30
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30
GRIN3A Q8TCU5 1/20 0.30
DDO Q99489 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631762 0.86 HPGD (0.36) RAB9AHPGDADORA3SMN1; SMN2
SCHEMBL16631748 0.81 ALDH1A1 (0.37) MAPK1RAB9AHPGDATAD2BRD4
SCHEMBL18081964 0.77 CRBN (0.36) KDM4EALDH1A1
SCHEMBL16631770 0.74 KDM4E (0.32) RAB9AHPGDADORA3KDM4ENPC1
SCHEMBL18080565 0.74 ALDH1A1 (0.32) KDM4EALDH1A1
SCHEMBL18081797 0.72 RAB9A (0.31) RAB9AHPGDKDM4ENPC1ALDH1A1
SCHEMBL18081806 0.72 RAB9A (0.33) RAB9AHPGDKDM4ENPC1ALDH1A1
SCHEMBL18081970 0.72 RAB9A (0.31) RAB9AHPGDKDM4ENPC1ALDH1A1
SCHEMBL25105413 0.67 TDP1 (0.39) MAPK1RAB9AHPGDALDH1A1
SCHEMBL18081975 0.67 ALDH1A1 (0.45) RAB9AHPGDKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 MAPK1 4185/4885RAB9A 3376/4885HPGD 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.